Leer L M, Cammenga M, van der Vorm E R, de Vijlder J J
Department of Experimental Pediatric Endocrinology, Academic Medical Centre, Amsterdam, The Netherlands.
Mol Cell Endocrinol. 1991 Jul;78(3):221-8. doi: 10.1016/0303-7207(91)90126-d.
Methimazole (1-methyl-2-mercaptoimidazole; MMI) increases thyroglobulin mRNA and thyroid peroxidase mRNA concentration in human thyroid cells and in FRTL-5 cells. MMI (1-10,000 microM) gives a dose-dependent increase of thyroglobulin concentration in the medium of human thyroid cells and FRTL-5 cells. The stimulation by MMI has no effect on the TSH-induced cAMP production and occurs in the presence or absence of thyrotropin (TSH). TSH increases the thyroglobulin and thyroid peroxidase mRNA synthesis in human thyroid cells and FRTL-5 cells. The accumulation of thyroglobulin in the medium has an optimum at 100 microU TSH/ml in FRTL-5 cells. This optimum can also be found in most human thyroid cell cultures.
甲巯咪唑(1-甲基-2-巯基咪唑;MMI)可增加人甲状腺细胞和FRTL-5细胞中甲状腺球蛋白mRNA和甲状腺过氧化物酶mRNA的浓度。MMI(1-10000微摩尔)可使人类甲状腺细胞和FRTL-5细胞培养基中的甲状腺球蛋白浓度呈剂量依赖性增加。MMI的刺激对促甲状腺激素(TSH)诱导的环磷酸腺苷(cAMP)产生没有影响,且在有或没有促甲状腺素(TSH)的情况下均会发生。TSH可增加人甲状腺细胞和FRTL-5细胞中甲状腺球蛋白和甲状腺过氧化物酶mRNA的合成。在FRTL-5细胞中,培养基中甲状腺球蛋白的积累在100微单位TSH/ml时达到最佳。在大多数人甲状腺细胞培养物中也能发现这种最佳状态。